BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 6, Issue 6
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (9102)
All Articles published online
The chart showing PDF series, WORD series, HTML series.
Item 
Count 
PDF683
WORD260
HTML5147
 Sum=6090
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1292
Download1711
 Sum=3003
Jul 18, 2015 (publication date) through Feb 27, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Orthopedics
ISSN
2218-5836
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Jul 18, 2015; 6(6): 457-461
Published online Jul 18, 2015. doi: 10.5312/wjo.v6.i6.457
Use of Teriparatide to improve fracture healing: What is the evidence?
Satish Babu, Nemandra A Sandiford, Mark Vrahas
Satish Babu, Core Surgical Trainee, St. George’s Hospital, London SW17 0QT, United Kingdom
Nemandra A Sandiford, Lower Limb and Tumor Reconstruction Fellow, University of British Columbia, Vancouver V5Z 1M9, British Columbia, Canada
Mark Vrahas, Orthopaedic Trauma Service, Massachusetts General Hospital, Boston, MA 02114, United States
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest statement: We, the authors of this scientific paper, do hereby state that we have no conflicts of interest to declare.
Correspondence to: Nemandra A Sandiford, FRCS (Trauma and Orthopaedics), Lower Limb and Tumor Reconstruction Fellow, University of British Columbia, 2329 West Mall, Vancouver V5Z 1M9, British Columbia, Canada. nemsandiford@hotmail.com
Telephone: +1-208-3069032
Received: February 12, 2015
Peer-review started: February 12, 2015
First decision: April 10, 2015
Revised: May 2, 2015
Accepted: June 1, 2015
Article in press: June 2, 2015
Published online: July 18, 2015
Processing time: 152 Days and 8.9 Hours
Core Tip

Core tip: Teriparatide contains the biologically active component of Parathyroid Hormone. It is utilised in osteoporosis for its ability to increase bone mass and prevent fractures. Research suggests Teriparatide may improve callus volume, callus mineralisation, bone mineral content and successful union. However most research come from animal models. Human research, whilst supporting Teriparatide use, mostly comprises low level evidence such as case series. Currently many United States physicians use Teriparatide “off license” for fractures and non-unions. We suggest more, well designed, human randomised controlled trials are required before Teriparatide can become a mainstream option in the conservative management of fractures and non-unions.
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345